Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
Research ArticleBrain

Evaluation of Microvascular Permeability with Dynamic Contrast-Enhanced MRI for the Differentiation of Primary CNS Lymphoma and Glioblastoma: Radiologic-Pathologic Correlation

P. Kickingereder, F. Sahm, B. Wiestler, M. Roethke, S. Heiland, H.-P. Schlemmer, W. Wick, A. von Deimling, M. Bendszus and A. Radbruch
American Journal of Neuroradiology August 2014, 35 (8) 1503-1508; DOI: https://doi.org/10.3174/ajnr.A3915
P. Kickingereder
aFrom the Departments of Neuroradiology (P.K., S.H., M.B., A.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Sahm
bNeuropathology (F.S., A.v.D.)
dGerman Cancer Consortium, Clinical Cooperation Unit Neuropathology (F.S., A.v.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Wiestler
cNeuro-oncology (B.W., W.W.), Neurology Clinic, University of Heidelberg Medical Center, Heidelberg, Germany
eClinical Cooperation Unit Neuro-oncology (B.W., W.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Roethke
fDepartment of Radiology (M.R., H.-P.S., A.R.), German Cancer Research Center, Heidelberg, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Heiland
aFrom the Departments of Neuroradiology (P.K., S.H., M.B., A.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.-P. Schlemmer
fDepartment of Radiology (M.R., H.-P.S., A.R.), German Cancer Research Center, Heidelberg, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Wick
cNeuro-oncology (B.W., W.W.), Neurology Clinic, University of Heidelberg Medical Center, Heidelberg, Germany
eClinical Cooperation Unit Neuro-oncology (B.W., W.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. von Deimling
bNeuropathology (F.S., A.v.D.)
dGerman Cancer Consortium, Clinical Cooperation Unit Neuropathology (F.S., A.v.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Bendszus
aFrom the Departments of Neuroradiology (P.K., S.H., M.B., A.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Radbruch
aFrom the Departments of Neuroradiology (P.K., S.H., M.B., A.R.)
fDepartment of Radiology (M.R., H.-P.S., A.R.), German Cancer Research Center, Heidelberg, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

BACKGROUND AND PURPOSE: Dynamic contrast-enhanced MR imaging can provide in vivo assessment of the microvasculature in intracranial tumors. The aim of the present study was to evaluate the diagnostic performance of dynamic contrast-enhanced MR imaging derived vascular permeability parameters, including the volume transfer constant, the volume of extravascular extracellular space, and the flux rate constant between the extravascular extracellular space and plasma, for the differentiation of primary CNS lymphoma and glioblastoma.

MATERIALS AND METHODS: Sixty glioblastomas and 11 primary central nervous system lymphomas were included. Pretreatment T1-weighted dynamic contrast-enhanced MR imaging with a 3D T1-weighted spoiled gradient-echo sequence was performed on a 3T MR imaging scanner. Perfusion parameters (volume transfer constant, the volume of extravascular extracellular space, and the flux rate constant) were measured on the basis of the Tofts-Kernmode model. The Mann-Whitney U test and receiver operating characteristic analysis were used to compare those parameters between primary central nervous system lymphoma and glioblastoma. Histopathologic correlation of dynamic contrast-enhanced MR imaging findings was performed by using reticulin staining and CD31 immunohistochemistry.

RESULTS: Median volume transfer constant and flux rate constant values were significantly higher in primary central nervous system lymphoma (0.145 ± 0.057 and 0.396 ± 0.088) than in glioblastoma (0.064 ± 0.021 and 0.230 ± 0.058) (P < .001, respectively). Median volume of extravascular extracellular space values did not differ significantly between primary central nervous system lymphoma (0.434 ± 0.165) and glioblastoma (0.319 ± 0.107). On receiver operating characteristic analysis, volume transfer constant had the best discriminative value for differentiating primary central nervous system lymphoma and glioblastoma (threshold, 0.093; sensitivity, 90.9%; specificity, 95.0%). Histopathologic evaluation revealed intact vascular integrity in glioblastoma despite endothelial proliferation, whereas primary central nervous system lymphoma demonstrated destroyed vessel architecture, thereby promoting vascular disintegrity.

CONCLUSIONS: Primary central nervous system lymphoma demonstrated significantly higher volume transfer constant and flux rate constant values compared with glioblastoma, implying a higher vascular permeability in primary central nervous system lymphoma. These findings confirm initial observations from perfusion CT and dynamic contrast-enhanced MR imaging studies, correlating with underlying histopathologic features, and may be useful in distinguishing primary central nervous system lymphoma from glioblastoma.

ABBREVIATIONS:

DCE-MRI
dynamic contrast-enhanced MRI
GB
glioblastoma
HE
hematoxylin-eosin
Kep
flux rate constant
Ktrans
volume transfer constant
PCNSL
primary central nervous system lymphoma
Ve
volume of extravascular extracellular space

Preoperative differentiation of primary central nervous system lymphomas (PCNSLs) and glioblastomas (GBs) is of high clinical relevance because neurosurgical strategies for PCNSL and GB favor a biopsy-only versus a maximal safe resection.1,2 Dynamic contrast-enhanced (DCE) MR imaging allows characterization of the vascular microenvironment in brain tumors by measurement of a range of parameters that reflect specific physiologic characteristics.3 Several recent studies have successfully applied DCE-MR imaging for quantitative estimates of vascular permeability parameters, essentially for glioma grading4⇓–6 and response assessment to antiangiogenic therapies.7,8 The most widely applied and accepted MR imaging standard to measure microvascular permeability is the DCE steady-state T1-weighted method, which is based on the 2-compartment pharmacokinetic model of Tofts and Kermode.9,10 Thereby the diffusive transport of low-molecular-weight contrast agent across the capillary endothelium from the blood plasma to the extravascular extracellular space is represented by the volume transfer constant (Ktrans, minute−1). Further parameters considered in this model are the flux rate constant (Kep, minute−1) between the extravascular extracellular space and the blood plasma and the volume (Ve) of the extravascular extracellular space per volume unit of tissue.3,9

Distinct structural and ultrastructural differences in the microenvironment of the tumor vasculature on histologic assessment have been reported for PCNSL and GB, suggesting increased vascular permeability for PCNSL.11 However, radiologic comparison of vascular permeability in PCNSL and GB has as yet only been performed with perfusion CT12,13 or with DSC-PWI processed with a mathematic leakage-correction model,14 which, in part, confirmed the increased vascular permeability for PCNSL. The aim of our study was to evaluate the diagnostic performance of DCE-MR imaging–derived vascular permeability parameters, including Ktrans, Kep, and Ve for the preoperative differentiation of PCNSL and GB. Furthermore, histopathologic correlation of DCE-MR imaging findings was performed for all patients by using reticulin and CD31 immunohistochemistry.

Materials and Methods

Patient Selection

Our institutional review board approved this retrospective study, and the requirement for patient informed consent was waived. Potentially eligible patients from October 2009 to June 2013 were identified on the basis of the diagnosis of PCNSL or GB. Next, for the selection of appropriate patients with PCNSL, only previously untreated, immunocompetent candidates were included. Thereby, 11 patients with PCNSLs with available DCE-MR imaging data on pretreatment MR imaging were available for inclusion in the present study. For selection of appropriate patients with GB, similar inclusion criteria were used. In detail, only previously untreated patients with the availability of pretreatment DCE-MR imaging data were included. Thereby, a control sample of 60 patients with GB was selected for inclusion in the present study.

MR Imaging

Images were acquired in the routine clinical work-up by using a 3T MR imaging system (Magnetom Verio/Trio Tim; Siemens, Erlangen, Germany) with a 12-channel head-matrix coil. Axial DCE-MR imaging was performed with a 3D spoiled gradient-echo sequence providing coverage of the entire brain by using the following parameters: matrix size, 128 × 128; FOV, 172 × 230 mm; TR, 5.28 ms; TE, 2.45 ms; flip angle, 10°; section thickness, 5 mm. Thereby, 22 dynamic acquisitions, each including 26 sections, were obtained every 13.34 seconds, resulting in a total measurement time of 4:53 minutes. After the third dynamic acquisition, a standard dose (0.1 mmol/kg body weight) of gadoterate meglumine (Dotarem; Guerbet, Aulnay-sous-Bois, France) was injected as a bolus through a pneumatically driven injection pump at an injection rate of 5 mL/s. After completion of the DCE-MR imaging sequence, standard postcontrast MPRAGE data were acquired with TI = 1100 ms, TE = 4 ms, TR = 1710 ms, and flip angle = 15°.

Image Postprocessing and Analysis

Postprocessing of DCE-MR imaging data was performed with dedicated postprocessing software (Tissue 4D; Siemens) based on the Tofts-Kermode model.9 First, motion correction was performed on the dynamic images on the basis of an elastic 3D registration technique. Signal intensity was then converted to gadoterate meglumine concentration, and the time–signal intensity curve was calculated. A value for the arterial input function was determined automatically on the basis of a mathematic simulation as described by Orton et al.15 After obtaining a kinetic modeling parameter map, a radiologist who was blinded to the patient's histology placed freehand ROIs within the entire contrast-enhancing tumor on each section of the DCE-MR images. Cystic or necrotic regions and normal vessels were avoided during region-of-interest placement. Following delineation of the entire contrast-enhancing tumor, vascular permeability parameters (Ktrans, Kep, and Ve) were automatically generated on the basis of the pixel information from all placed freehand ROIs.

Histopathologic Correlation

To assess whether DCE-MR imaging–derived vascular permeability parameters correlate with vascular integrity on histopathology, we performed reticulin (Tibor-Pap) and hematoxylin-eosin (HE) staining of formalin-fixed paraffin-embedded tumor tissue for all patients. Thereby, both HE and Tibor-Pap stains were used to illustrate the architecture of the tumor and vessels, whereas Tibor-Pap highlights the reticulin fibers in the outer border of the vessel wall, which may be destroyed and detached from the inner endothelium membrane in case of decreased vascular integrity.16 Additionally, in cases in which the endothelial architecture was not evident from HE and reticulin staining, CD31 immunohistochemistry, highlighting endothelial cells, was performed. Tissue was provided by the Department of Neuropathology, Institute of Pathology, University of Heidelberg Medical Center, Germany, in accordance with local ethics approval. Sections cut to 3 μm were processed by using a BenchMark XT immunostainer (Ventana Medical Systems, Tucson, Arizona). Reticulin and HE staining was performed by applying standard protocols. Pretreatment for antigen retrieval was followed by incubation with antihuman CD31 antibody (Dako, Glostrup, Denmark). Incubation was followed by Ventana standard signal amplification, UltraWash, counter-staining with 1 drop of hematoxylin for 4 minutes and 1 drop of bluing reagent for 4 minutes. For visualization, the UltraView Universal DAB Detection Kit (Ventana Medical Systems) was used. Reticulin, HE, and CD31 stains were analyzed by a neuropathologist by using a Olympus BX-50 microscope (Olympus America, Lake Success, New York), and vascular integrity was rated as intact or decreased.

Statistical Analysis

Statistical analysis was performed by using the Statistical Package for the Social Sciences Statistics, Version 20.0 (IBM, Armonk, New York). A Mann-Whitney U test was used to compare vascular permeability parameters (Ktrans, Kep, and Ve) between PCNSL and GB. Receiver operating characteristic analysis was performed to determine the optimum thresholds for discrimination of PCNSL and GB. P values < .05 were considered significant.

Results

Figure 1 shows a boxplot of DCE-MR imaging–derived vascular permeability parameters, including Ktrans, Kep, and Ve. Median Ktrans values were higher in PCNSL (0.145 ± 0.057; 95% CI, 0.106–0.183; range, 0.071–0.285) than in GB (0.064 ± 0.021; 95% CI, 0.060–0.071; range, 0.024–0.121) (P < .001). Similarly, median Kep values were higher in PCNSL (0.396 ± 0.088; 95% CI, 0.305–0.423; range, 0.225–0.509) than in GB (0.230 ± 0.058; 95% CI, 0.215–0.245; range, 0.118–0.425) (P < .001). Median Ve values did not differ significantly between PCNSL (0.434 ± 0.165; 95% CI, 0.311–0.534; range, 0.172–0.684) and GB (0.319 ± 0.107; 95% CI, 0.292–0.347; range, 0.104–0.524). On receiver operating characteristic analysis, Ktrans had the best discriminative value for differentiating PCNSL and GB (area under the curve, 95.6%; threshold, 0.093; sensitivity, 90.9%; specificity, 95.0%) compared with Kep (area under the curve, 89.1%; threshold, 0.272; sensitivity, 90.9%; specificity; 78.3%) or Ve (area under the curve, 68.6%; threshold, 0.410; sensitivity, 63.6%; specificity, 76.7%). The workflow of postprocessing DCE-MR imaging data of 2 representative patients with PCNSL and GB is shown in Fig 2.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Boxplots of microvascular permeability parameters in primary CNS lymphoma and glioblastoma, including the volume transfer constant (minute−1), the volume of extravascular extracellular space per volume unit of tissue, and the flux rate constant between extravascular extracellular space and plasma (minute−1). The solid line inside the box represents the median value, while the edges represent the 25th and 75th percentiles. The straight line (bar) on each box indicates the range of data distribution. Circles represent outliers (values >1.5 box length from the 75th and 25th percentile).

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Tissue concentration of contrast agent after bolus injection of 0.1 mmol/g of gadoterate meglumine (left column) in primary CNS lymphoma (upper row) and glioblastoma (lower row). Note the differences in the relative enhancement curve within the region of interest, encompassing the tumor (red square), which peaks at 0.53 in PCNSL and at 0.34 in GB. Perfusion parameters from kinetic modeling parameter maps (right column) were measured by using freehand region-of-interest placement within the solid part of the entire contrast-enhancing tumor (dashed red line within the zoomed kinetic maps; only 1 section is shown here). In these samples, median Ktrans values were 0.147 ± 0.031 for PCNSL and 0.045 ± 0.014 for GB.

On histopathologic assessment of vascular integrity, tissue samples from PCNSL demonstrated destroyed vessel architecture in each case. Thereby, the outer border of the vessel wall was infiltrated by tumor cells (ie, angiocentric growth pattern), destroyed, and detached from the inner endothelial membrane, thereby contributing to vascular disintegrity (Fig 3, left column). In contrast, vascular integrity was rated as intact for all GBs (Fig 3, right column).

Fig 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 3.

Histopathologic assessment of vascular integrity from those patients shown in Fig 2 (original magnification ×200 for all stains): Immunohistochemistry for CD31 (left column) highlights endothelium in primary CNS lymphoma (PCNSL) (upper row) and glioblastoma (GB) tissue (lower row). Black arrows point to the endothelium and indicate the actual lumen of the vessel in PCNSL tissue. In contrast, white arrows in the reticulin staining of the PCNSL tissue (upper row, right) illustrate the outer border of the vessel wall, which is infiltrated by tumor cells, destroyed, and detached from the inner endothelial membrane and thus contributing to decreased vascular integrity. White arrows in the reticulin staining of the GB tissue (lower row, right) underline the integer basal membrane of vessels despite endothelial proliferation.

Discussion

The present study evaluated the diagnostic performance of DCE-MR imaging–derived vascular permeability parameters to facilitate the preoperative differentiation of PCNSL and GB. As a principal finding, our study shows that PCNSL demonstrates significantly higher Ktrans and Kep values on DCE-MR imaging compared with GB, thereby implying a greater degree of BBB disruption and thus higher vascular permeability in PCNSL, ultimately confirming initial observations from perfusion CT and DSC-MR imaging studies.13,14 Furthermore, we could demonstrate that these findings correlate with underlying histopathologic features, with intact vascular integrity for GB and destroyed vessel architecture in PCNSL, thereby promoting vascular disintegrity in the latter group.

Radiologic comparison of vascular permeability patterns between PCNSL and GB was initially performed by Warnke et al,13 who demonstrated significantly higher Ktrans values on CT perfusion imaging for PCNSL compared with GB. These results were in contrast to a subsequent study by Schramm et al,12 who performed CT perfusion imaging in a series of 31 high-grade gliomas and 8 PCNSLs, reporting no significant difference in Ktrans values on Patlak analysis. This pharmacokinetic model assumes that the transfer of the contrast agent across the BBB is unidirectional from the blood plasma to the extravascular extracellular space throughout the entire measurement.17 In contrast, the equation of Tofts and Kermode9 also considers the backflow of contrast agent from the extravascular extracellular space to the blood plasma. However, neglecting the backflow of the contrast agent in the Patlak model essentially underestimates Ktrans in brain tumors18⇓–20 and may explain the nonsignificant differences in the study of Schramm et al.12

Recently, Toh et al14 performed a study on 15 patients with PCNSL and 20 with GB, evaluating the pseudoleakage parameter K2 derived from DSC-PWI with a mathematic leakage-correction model, reporting significant higher K2 values in PCNSL compared with GB. This model is based on the assumption that in brain tumors with substantial BBB breakdown, contrast agent extravasates into the extravascular extracellular space, thereby reducing the T2* DSC-PWI signal-intensity loss by signal-intensity increase in regions where T1 effects are significant.21,22 In such instances, CBV will be underestimated. Therefore Boxerman et al21,22 and Weisskoff et al23 proposed a mathematic leakage-correction model in which linear fitting is used to determine the voxelwise deviation from nonleaky reference tissue and, by removing the leakage term, allowing generation of both corrected CBV maps and first-order estimates of vascular permeability. Although direct comparison is limited by differences in study populations and methodology, the diagnostic performance of DCE-derived Ktrans in the present study was superior compared with the mathematic leakage-corrected DSC-derived K2 in the study of Toh et al14 (area under the curve on receiver operating characteristic analysis, 95.6% versus 77.1%). Due to the complex relationship between contrast agent concentration in tissue and the measured change in signal intensity on DSC-PWI, a positive relationship between DSC-PWI and DCE-MR imaging–derived vascular permeability parameters (ie, K2 and Ktrans) may only exist with high flip angles on DSC-PWI (90°).24

Furthermore, the DSC-PWI leakage-correction model assumes that the contrast agent arrives at the same time in the tumor and unaffected normal brain tissue and that tumor and nontumor tissue have equal MTT.25,26 However, tumor vasculature is extremely variable and heterogeneous,27 and elevated tumor MTT may cause overestimation of CBV and underestimation of K2.22,26 Therefore, Bjornerud et al26 recently described a novel leakage-correction algorithm for evaluating microvascular permeability on DSC-PWI that is insensitive to MTT. However, the clinical value of such mathematically leakage-corrected DSC-PWI permeability parameters has to be determined in future studies and correlated with those from DCE-MR imaging.

Previous studies have demonstrated that CBV values significantly differ between PCNSL and GB, with only modest increased values in the former and markedly increased values in the latter group.14,28⇓–30 These results may be explained by the differences in neovascularization, which is a hallmark in GB,31 however, an unusual feature in (non-AIDS-related) PCNSL.32 Thus, the microvascular blood flow to the tumor tissue in GB is often hampered by an abnormal tumor vasculature due to neovascularization comprising immature or defective endothelium, tortuosity, and thrombosis. Hence, the uptake of contrast agent by the GB tissue is likely limited by blood flow.10 In contrast, the absence of neovascularization and the substantial disruption of the BBB in PCNSL is related to the clustering of tumor cells within and around pre-existing brain vessels (ie, angiocentric growth pattern).33 These distinct morphologic differences may make the uptake of contrast agent in PCNSL less flow-limited compared with GB, which may serve as an explanation for the significantly higher Ktrans and Kep values in PCNSL in the present study.

A potential limitation of the present study is that due to the given section thickness of the DCE-MR imaging sequence, volume-averaging effects may have limited exact region-of-interest placement for precise delineation of the contrast-enhancing tumor. Another limitation is that DCE-MR imaging–derived vascular permeability parameters may be affected by several factors, including blood flow; blood volume; endothelial permeability; endothelial permeability surface area; and hydrostatic, interstitial, and osmotic gradients across the endothelium.10 Thus, we could not definitely state whether changes in Ktrans and Kep were solely due to changes in vascular permeability or to what extent other factors may have contributed.

Conclusions

PCNSL demonstrated significantly higher Ktrans and Kep values compared with GB, thereby implying a higher vascular permeability in PCNSL. These findings correlate with underlying histopathologic features, with intact vascular integrity for GB and destroyed vessel architecture in PCNSL, thereby promoting vascular disintegrity in the latter group, and they may improve the preoperative differentiation of PCNSL and GB.

Footnotes

  • Disclosures: Heinz-Peter Schlemmer—UNRELATED: Consultancy: Siemens, Grants/Grants Pending: Siemens,* Payment for Lectures (including service on Speakers Bureaus): Siemens, Curagita, Covidien; Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: Siemens. Wolfgang Wick—UNRELATED: Consultancy: Roche, Merck Sharp & Dohme, Payment for Lectures (including service on Speakers Bureaus): Roche, Prime Oncology, Patents (planned, pending or issued): IDH diagnostic antibody. Martin Bendszus—UNRELATED: Board Membership: Vascular Dynamics, Payment for Lectures (including service on Speakers Bureaus): Novartis, Roche, Codman, Guerbet. *Money paid to the institution.

  • Paper previously presented at: European Congress of Radiology, March 6–10, 2014; Vienna, Austria.

REFERENCES

  1. 1.↵
    1. Stupp R,
    2. Mason WP,
    3. van den Bent MJ,
    4. et al
    . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96
    CrossRefPubMed
  2. 2.↵
    1. Schlegel U
    . Primary CNS lymphoma. Ther Adv Neurol Disord 2009;2:93–104
    Abstract/FREE Full Text
  3. 3.↵
    1. Tofts PS
    . T1-weighted DCE imaging concepts: modelling, acquisition and analysis. MAGNETOM Flash 2010;30–39
  4. 4.↵
    1. Nguyen TB,
    2. Cron GO,
    3. Mercier JF,
    4. et al
    . Diagnostic accuracy of dynamic contrast-enhanced MR imaging using a phase-derived vascular input function in the preoperative grading of gliomas. AJNR Am J Neuroradiol 2012;33:1539–45
    Abstract/FREE Full Text
  5. 5.↵
    1. Cha S,
    2. Yang L,
    3. Johnson G,
    4. et al
    . Comparison of microvascular permeability measurements, Ktrans, determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. AJNR Am J Neuroradiol 2006;27:409–17
    Abstract/FREE Full Text
  6. 6.↵
    1. Mills SJ,
    2. Patankar TA,
    3. Haroon HA,
    4. et al
    . Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006;27:853–58
    Abstract/FREE Full Text
  7. 7.↵
    1. Sorensen AG,
    2. Batchelor TT,
    3. Zhang WT,
    4. et al
    . A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009;69:5296–300
    Abstract/FREE Full Text
  8. 8.↵
    1. Zhang W,
    2. Kreisl T,
    3. Solomon J,
    4. et al
    . Acute effects of bevacizumab on glioblastoma vascularity assessed with DCE-MRI and relation to patient survival. In: Proceedings of the 17th Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, Honolulu, Hawaii; April 18–24, 2009:282
  9. 9.↵
    1. Tofts PS,
    2. Kermode AG
    . Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357–67
    CrossRefPubMed
  10. 10.↵
    1. Cha S
    . Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006;27:475–87
    FREE Full Text
  11. 11.↵
    1. Molnár PP,
    2. O'Neill BP,
    3. Scheithauer BW,
    4. et al
    . The blood-brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death. Neuro Oncol 1999;1:89–100
    Abstract/FREE Full Text
  12. 12.↵
    1. Schramm P,
    2. Xyda A,
    3. Klotz E,
    4. et al
    . Dynamic CT perfusion imaging of intra-axial brain tumours: differentiation of high-grade gliomas from primary CNS lymphomas. Eur Radiol 2010;20:2482–90
    CrossRefPubMed
  13. 13.↵
    1. Warnke PC,
    2. Timmer J,
    3. Ostertag CB,
    4. et al
    . Capillary physiology and drug delivery in central nervous system lymphomas. Ann Neurol 2005;57:136–39
    CrossRefPubMed
  14. 14.↵
    1. Toh CH,
    2. Wei KC,
    3. Chang CN,
    4. et al
    . Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction. AJNR Am J Neuroradiol 2013;34:1145–49
    Abstract/FREE Full Text
  15. 15.↵
    1. Orton MR,
    2. d'Arcy JA,
    3. Walker-Samuel S,
    4. et al
    . Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI. Phys Med Biol 2008;53:1225–39
    CrossRefPubMed
  16. 16.↵
    1. Louis DN,
    2. Ohgaki H,
    3. Wiestler OD,
    4. et al
    . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109
    CrossRefPubMed
  17. 17.↵
    1. Patlak CS,
    2. Blasberg RG,
    3. Fenstermacher JD
    . Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1–7
    CrossRefPubMed
  18. 18.↵
    1. Bagher-Ebadian H,
    2. Jain R,
    3. Nejad-Davarani SP,
    4. et al
    . Model selection for DCE-T1 studies in glioblastoma. Magn Reson Med 2012;68:241–51
    CrossRefPubMed
  19. 19.↵
    1. Bergamino M,
    2. Saitta L,
    3. Barletta L,
    4. et al
    . Measurement of blood-brain barrier permeability with T1-weighted dynamic contrast-enhanced MRI in brain tumors: a comparative study with two different algorithms. ISRN Neurosci 2013;2013:6
  20. 20.↵
    1. Jain R,
    2. Bagher-Ebadian H,
    3. Narang J,
    4. et al
    . Optimal period of linearity using Patlak analysis in brain tumors. In: Proceedings of the 18th Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, Stockholm, Sweden; May 1–7, 2010:4090
  21. 21.↵
    1. Boxerman J,
    2. Schmainda K,
    3. Weisskoff R
    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67
    Abstract/FREE Full Text
  22. 22.↵
    1. Boxerman JL,
    2. Prah DE,
    3. Paulson ES,
    4. et al
    . The role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard. AJNR Am J Neuroradiol 2012;33:1081–87
    Abstract/FREE Full Text
  23. 23.↵
    1. Weisskoff RM,
    2. Boxerman JL,
    3. Sorensen AG,
    4. et al
    . Simultaneous blood volume and permeability mapping using a single Gd-based contrast injection. In: Proceedings of the 2nd Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, San Francisco, California; August 6–12, 1994
  24. 24.↵
    1. Emblem K,
    2. Mouridsen K,
    3. Borra R,
    4. et al
    . Does DSC-derived CA extravasation correlate with DCE Ktrans? In: Proceedings of the 19th International Society of Magnetic Resonance in Medicine, Montreal, Quebec, Canada; May 6–13, 2011
  25. 25.↵
    1. Emblem KE,
    2. Bjornerud A,
    3. Mouridsen K,
    4. et al
    . T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI. Part II. Predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. J Cereb Blood Flow Metab 2011;31:2054–64
    CrossRefPubMed
  26. 26.↵
    1. Bjornerud A,
    2. Sorensen AG,
    3. Mouridsen K,
    4. et al
    . T1- and T2*-dominant extravasation correction in DSC-MRI: part I–theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab 2011;31:2041–53
    CrossRefPubMed
  27. 27.↵
    1. McDonald DM,
    2. Choyke PL
    . Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9:713–25
    CrossRefPubMed
  28. 28.↵
    1. Hartmann M,
    2. Heiland S,
    3. Harting I,
    4. et al
    . Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 2003;338:119–22
    CrossRefPubMed
  29. 29.↵
    1. Wang S,
    2. Kim S,
    3. Chawla S,
    4. et al
    . Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2011;32:507–14
    Abstract/FREE Full Text
  30. 30.↵
    1. Liao W,
    2. Liu Y,
    3. Wang X,
    4. et al
    . Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Acta Radiol 2009;50:217–25
    Abstract/FREE Full Text
  31. 31.↵
    1. Wong ET,
    2. Brem S
    . Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw 2008;6:515–22
    Abstract/FREE Full Text
  32. 32.↵
    1. Lister A,
    2. Abrey LE,
    3. Sandlund JT
    . Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2002:283–96
  33. 33.↵
    1. Tonn JC,
    2. Westphal M,
    3. Rutka JT,
    4. et al.
    1. Schlegel U,
    2. Hochberg F
    . Primary CNS lymphoma. In: Tonn JC, Westphal M, Rutka JT, et al., eds. Neuro-Oncology of CNS Tumors. Heidelberg, Germany: Springer-Verlag; 2006:292–302
  • Received November 3, 2013.
  • Accepted after revision January 9, 2014.
  • © 2014 by American Journal of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 35 (8)
American Journal of Neuroradiology
Vol. 35, Issue 8
1 Aug 2014
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of Microvascular Permeability with Dynamic Contrast-Enhanced MRI for the Differentiation of Primary CNS Lymphoma and Glioblastoma: Radiologic-Pathologic Correlation
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Evaluation of Microvascular Permeability with Dynamic Contrast-Enhanced MRI for the Differentiation of Primary CNS Lymphoma and Glioblastoma: Radiologic-Pathologic Correlation
P. Kickingereder, F. Sahm, B. Wiestler, M. Roethke, S. Heiland, H.-P. Schlemmer, W. Wick, A. von Deimling, M. Bendszus, A. Radbruch
American Journal of Neuroradiology Aug 2014, 35 (8) 1503-1508; DOI: 10.3174/ajnr.A3915

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Evaluation of Microvascular Permeability with Dynamic Contrast-Enhanced MRI for the Differentiation of Primary CNS Lymphoma and Glioblastoma: Radiologic-Pathologic Correlation
P. Kickingereder, F. Sahm, B. Wiestler, M. Roethke, S. Heiland, H.-P. Schlemmer, W. Wick, A. von Deimling, M. Bendszus, A. Radbruch
American Journal of Neuroradiology Aug 2014, 35 (8) 1503-1508; DOI: 10.3174/ajnr.A3915
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Comparison of Dynamic Contrast-Enhancement Parameters between Gadobutrol and Gadoterate Meglumine in Posttreatment Glioma: A Prospective Intraindividual Study
  • Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma
  • Differentiation of Enhancing Glioma and Primary Central Nervous System Lymphoma by Texture-Based Machine Learning
  • Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma
  • The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Predictors of Reperfusion in Patients with Acute Ischemic Stroke
  • Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis
  • Progression of Microstructural Damage in Spinocerebellar Ataxia Type 2: A Longitudinal DTI Study
Show more BRAIN

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2022 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2023 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire